Publications

First European Phase Ii Trial of Intravenous (Iv) Cetuximab (Cet) and Hepatic Artery Infusion (Hai) of Irinotecan, 5-Fluorouracil and Oxaliplatin in Patients with Unresectable Liver Metastases from Wt Kras Colorectal Cancer (Crc) After Systemic Therapy Failure (Optiliv, Nct00852228)

AuthID
P-005-EWZ

Author(s)

Levi, F

Ducreux, M

Hebbar, M

Rougier, P

Focan, CNJ

Guimbaud, R

Carvalho, C

Tumolo, S

Innominato, PF

Ajavon, Y

Castaing, D

De Baere, T

Karaboue, A

Lepere, C

Boige, V

Proux, L

Adam, R

Bouchahda, M

Group Author(s)

ARTBC Int

Document Type

Abstract

Year published

2012

Published

in JOURNAL OF CLINICAL ONCOLOGY, ISSN: 0732-183X

Volume: 30, Issue: 15

Conference

48Th Annual Meeting of the American-Society-Of-Clinical-Oncology (Asco), Date: JUN 01-06, 2012, Location: Chicago, IL, Sponsors: Amer Soc Clin Oncol (ASCO)

Indexing

Wos^®

Metadata
Sources

Publication Identifiers

Wos: WOS:000318009805028

Source Identifiers

ISSN: 0732-183X

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

First European Phase Ii Trial of Intravenous (Iv) Cetuximab (Cet) and Hepatic Artery Infusion (Hai) of Irinotecan, 5-Fluorouracil and Oxaliplatin in Patients with Unresectable Liver Metastases from Wt Kras Colorectal Cancer (Crc) After Systemic Therapy Failure (Optiliv, Nct00852228)

Useful Links

Get Help

Federated Authentication (Click on the image)

First European Phase Ii Trial of Intravenous (Iv) Cetuximab (Cet) and Hepatic Artery Infusion (Hai) of Irinotecan, 5-Fluorouracil and Oxaliplatin in Patients with Unresectable Liver Metastases from Wt Kras Colorectal Cancer (Crc) After Systemic Therapy Failure (Optiliv, Nct00852228)

Useful Links

Get Help